Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

2期进行中（已停止招募） NCT04739800

适应症	Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
分期	2期
申办方	National Cancer Institute (NCI)
状态	进行中（已停止招募）
受试者人数	120 人
干预（药物）	Biospecimen Collection, Cediranib Maleate, Computed Tomography, Computed Tomography with Contrast, Durvalumab
开始日期	2021年6月10日
完成日期	2023年1月26日
结果公布日	2024年6月18日

摘要

This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and

Progression Free Survival

From start of treatment to time of progression or death, whichever occurs first. Median follow-up time was 4.8 months (Inter-Quartile Range: 2.0-7.9 months). · Months

Arm I (Paclitaxel, Doxorubicin, Topotecan Hydrochloride))	4.2 Months
Arm II (Durvalumab, Cediranib Maleate, Olaparib)	2.6 Months
Arm III (Durvalumab, Cediranib Maleate)	2.3 Months
Arm IV (Cediranib Maleate, Olaparib)	2.3 Months

Hazard Ratio (HR)	1.00 (95% CI 0.44–2.31)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulo — Beth Israel Deaconess Medical Center
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, — M.D. Anderson Cancer Center
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carbop — AstraZeneca
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Trea — National Cancer Institute (NCI)
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or — National Cancer Institute (NCI)
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Can — National Cancer Institute (NCI)

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский